CSIMarket
 
Becton Dickinson And Company  (BDX)
Other Ticker:  
 
 
Price: $241.0200 $3.68 1.551%
Day's High: $237.19 Week Perf: 2.3 %
Day's Low: $ 235.57 30 Day Perf: 2.45 %
Volume (M): 40 52 Wk High: $ 280.62
Volume (M$): $ 9,429 52 Wk Avg: $250.38
Open: $237.39 52 Wk Low: $215.90



 Market Capitalization (Millions $) 69,232
 Shares Outstanding (Millions) 287
 Employees 72,000
 Revenues (TTM) (Millions $) 18,870
 Net Income (TTM) (Millions $) 1,779
 Cash Flow (TTM) (Millions $) -1,233
 Capital Exp. (TTM) (Millions $) 973

Becton Dickinson And Company
BD is a medical technology company engaged principally in the manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry and the general public.

BD's operations consist of three worldwide business segments: BD Medical ('Medical') (formerly BD Medical Systems), BD Diagnostics ('Diagnostics') (formerly BD Clinical Laboratory Solutions) and BD Biosciences ('Biosciences').


BD Medical

The major products in this segment are hypodermic syringes and needles for injection, insulin syringes and pen needles and blood glucose monitoring systems for diabetes care, infusion therapy devices, prefillable drug delivery systems and surgical blades and scalpels. This segment also includes specialty blades and cannulas for ophthalmic surgery procedures, anesthesia needles, critical care systems, elastic support products and thermometers.

BD Diagnostics

The major products in this segment are clinical and industrial microbiology products, sample collection products, specimen management systems, molecular diagnostic instruments and other diagnostic systems, including immunodiagnostic test kits. This segment also includes consulting services.

BD Biosciences

This segment provides integrated systems, products and services for a variety of applications in life sciences. The major products are flow cytometry systems for cell analysis, monoclonal antibodies for biomedical research,
molecular biology products for the study of genes and their functions, cell growth and screening products, and labware products.

INTERNATIONAL OPERATIONS

BD's products are manufactured and sold worldwide. The principal markets for BD's products outside the United States are Europe, Japan, Asia Pacific, Canada and Latin America. The principal products sold by BD outside of the United States are hypodermic needles and syringes, insulin syringes and pen needles, diagnostic systems, VACUTAINER'r' brand blood collection products, HYPAK'r' brand prefillable syringe systems, and infusion therapy products. BD has manufacturing operations outside the United States in Brazil, China, France,
Germany, India, Ireland, Japan, Korea, Mexico, Pakistan, Singapore, Spain, Sweden and the United Kingdom.

Foreign economic conditions and exchange rate fluctuations have caused the profitability from foreign revenues to fluctuate more than the profitability from domestic revenues. BD believes its activities in some countries outside the United States involve greater risk than its domestic business due to the foregoing factors, as well as local commercial and economic policies and political uncertainties.

COMPETITION

A number of companies, some of which are more specialized than BD with respect to particular markets, compete in the medical technology field. In each such case, competition involves only a part of BD's product lines. Competition in BD's markets is based on a combination of factors, including price, quality, service, reputation, distribution and promotion. Ongoing investments in research, quality management, quality improvement, product innovation and productivity improvement are required to maintain an advantage in the
competitive environments in which BD operates.



   Company Address: 1 Becton Drive, Franklin Lakes, 7417 NJ
   Company Phone Number: 847-6800   Stock Exchange / Ticker: NYSE BDX
   BDX is expected to report next financial results on February 02, 2023.


Customers Net Income fell by BDX's Customers Net Profit Margin fell to

-53.41 %

3.1 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAXNYSE     
MMM   -1.18%    
ABC        4.74% 
ABT        1.08% 
CAH        1.2% 
DHR   -0.4%    
• View Complete Report
   



Mexco Energy Corporation

The Oil And Gas Production company disclosed a revenue surge by very active 83.895%, amid the financial span closing Sep 30 2022

MXC delivered very bewildering recent numbers in the most recent fiscal period, where Sales soared by 83.895 % to $2.32 millions, while MXCs' income per share truly advanced by 189.47 % to $0.55 per share, from the same quarter a year ago.